Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1183/13993003.02554-2020 http://scihub22266oqcxt.onion/10.1183/13993003.02554-2020 C7377212!7377212!32703771     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Eur+Respir+J 2020 ; 56 (4): ä Nephropedia Template TP {{tp|p=32703771|t=2020. Confronting and mitigating the risk of COVID-19 associated pulmonary aspergillosis |pdf=|usr=}}{{32703771}} gab.com Text Confronting and mitigating the risk of COVID-19 associated pulmonary aspergillosis JO: Eur Respir J http://www.kidney.de/pget.php?&tw=1&pmid=32703771 #FOAvip The coronavirus disease 2019 (COVID-19) virus caused a wide spectrum of disease in healthy individuals, as well as those with common comorbidities [1]. Severe COVID-19 is characterised by acute respiratory distress syndrome (ARDS) secondary to viral pneumonitis, treatment of which may require mechanical ventilation or extracorporeal membrane oxygenation [2]. Clinicians are alert to the possibility of bacterial co-infection as a complication of lower respiratory tract viral infection; for example, a recent review found that 72% of patients with COVID-19 received antimicrobial therapy [3]. However, the risk of fungal co-infection, in particular COVID-19 associated pulmonary aspergillosis (CAPA), remains underappreciated. Twit Text FOAVip Confronting and mitigating the risk of COVID-19 associated pulmonary aspergillosis ????Eur Respir J http://www.kidney.de/pget.php?&tw=1&pmid=32703771 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32703771 #FOAvip English Wikipedia <ref>{{Cite pmid|32703771}}</ref> Confronting and mitigating the risk of COVID-19 associated pulmonary aspergillosis #MMPMID32703771 Armstrong-James D; Youngs J; Bicanic T; Abdolrasouli A; Denning DW; Johnson E; Mehra V; Pagliuca T; Patel B; Rhodes J; Schelenz S; Shah A; van de Veerdonk FL; Verweij PE; White PL; Fisher MC Eur Respir J 2020[Oct]; 56 (4): ä PMID32703771show ga The coronavirus disease 2019 (COVID-19) virus caused a wide spectrum of disease in healthy individuals, as well as those with common comorbidities [1]. Severe COVID-19 is characterised by acute respiratory distress syndrome (ARDS) secondary to viral pneumonitis, treatment of which may require mechanical ventilation or extracorporeal membrane oxygenation [2]. Clinicians are alert to the possibility of bacterial co-infection as a complication of lower respiratory tract viral infection; for example, a recent review found that 72% of patients with COVID-19 received antimicrobial therapy [3]. However, the risk of fungal co-infection, in particular COVID-19 associated pulmonary aspergillosis (CAPA), remains underappreciated. äConfronting and mitigating the risk of COVID-19 associated pulmonary a(epmc).pdf DeepDyve Pubget Overpricing